- Home
- PACB vs OCGN Comparison
PACB vs OCGN Comparison
Compare PACB & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACB
- OCGN
- Stock Information
- Founded
- PACB 2000
- OCGN 2013
- Country
- PACB United States
- OCGN United States
- Employees
- PACB N/A
- OCGN N/A
- Industry
- PACB Biotechnology: Laboratory Analytical Instruments
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PACB Industrials
- OCGN Health Care
- Exchange
- PACB Nasdaq
- OCGN Nasdaq
- Market Cap
- PACB 369.5M
- OCGN 321.7M
- IPO Year
- PACB 2010
- OCGN N/A
- Fundamental
- Price
- PACB $1.41
- OCGN $1.71
- Analyst Decision
- PACB Buy
- OCGN Strong Buy
- Analyst Count
- PACB 7
- OCGN 3
- Target Price
- PACB $1.90
- OCGN $6.00
- AVG Volume (30 Days)
- PACB 6.8M
- OCGN 8.4M
- Earning Date
- PACB 11-06-2025
- OCGN 11-07-2025
- Dividend Yield
- PACB N/A
- OCGN N/A
- EPS Growth
- PACB N/A
- OCGN N/A
- EPS
- PACB N/A
- OCGN N/A
- Revenue
- PACB $156,110,000.00
- OCGN $4,754,000.00
- Revenue This Year
- PACB $6.17
- OCGN N/A
- Revenue Next Year
- PACB $15.63
- OCGN N/A
- P/E Ratio
- PACB N/A
- OCGN N/A
- Revenue Growth
- PACB N/A
- OCGN N/A
- 52 Week Low
- PACB $0.85
- OCGN $0.52
- 52 Week High
- PACB $2.72
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- PACB 51.90
- OCGN 61.41
- Support Level
- PACB $1.39
- OCGN $1.31
- Resistance Level
- PACB $1.60
- OCGN $1.88
- Average True Range (ATR)
- PACB 0.10
- OCGN 0.15
- MACD
- PACB 0.02
- OCGN 0.01
- Stochastic Oscillator
- PACB 48.15
- OCGN 59.80
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").